Download a complete bibliography from each of our ongoing investigational programs below.
Tebipenem HBR
Monitoring the in vitro activity of tebipenem, an orally available carbapenem agent, against a current collection of surveillance Enterobacteriaceae clinical isolates (2018)
Tebipenem HBR
SPR994: oral carbapenem for the treatment of complicated urinary tract infections
Tebipenem HBR
Evaluation of tebipenem activity tested against a collection of isogenic Escherichia coli strains producing various clinically relevant β-lactamases
SPR720
Evaluating the sterilizing activity of SPR720 in combination therapy against Mycobacterium tuberculosis infection in mice
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera - pipeline drugs to treat
Tebipenem HBR
Single-and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose
SPR720
A GLP 28-day repeat dose toxicology study of SPR720 in monkeys
SPR720
SPR720: novel oral therapy for non-tuberculous Mycobacterial (NTM) infections
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera
Tebipenem HBR
Arends SJR, Rhomberg PR, Cotroneo N, et al. Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae isolates, including a challenge set of organisms. Antimicrob Agents Chemother. 2019 May 24;63(6):e02618-18.
Tebipenem HBR
Escherichia coli from urinary tract infections in Europe in 2017 are increasingly multidrug-resistant to oral antibiotics in an era of co-resistance to extended-spectrum beta-lactamases
Tebipenem HBR
Activity of tebipenem, an oral carbapenem, against multidrug-resistant urinary tract infection-causing pathogens with characterized resistance mechanisms collected in Europe and the United States in 2016
Tebipenem HBR
Lacasse E, Brouillette E, Larose A, et al. In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
Thomas J, Navre M, Rubio A, Coukell A. Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery. ACS Infect Dis. 2018 Nov 9;4(11):1536-1539.
SPR720
Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01503-18.
Tebipenem HBR
Rubio A, Pucci MJ, Jain A. Characterization of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis. 2018 Oct 12;4(10):1436-1438.
Tebipenem HBR
SPR994 (oral carbapenem prodrug): what’s in the pipeline?
Tebipenem HBR
Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant versus susceptible urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
Current oral (PO) regimen options are suboptimal for hospitalized patients with urinary tract infections (UTI) due to contemporary resistant Enterobacteriaceae (ENT): a multicenter analysis
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multidrug resistant Enterobacteriaceae in a hollow fibre infection model
Tebipenem HBR
The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of SPR994 for multidrug resistant Enterobacteriaceae
Tebipenem HBR
Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522.
Tebipenem HBR
Antimicrobial activity of tebipenem (SPR859) against a global challenge set of Enterobacteriaceae isolates
Tebipenem HBR
In vitro activity of tebipenem (SPR859), tebipenem-pivoxil (SPR994) and meropenem against a broad spectrum of anaerobic bacteria
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in an acute murine thigh infection caused by Escherichia coli and Klebsiella pneumoniae
Tebipenem HBR
Frequency of spontaneous mutations conferring reduced susceptibility to tebipenem (SPR859) among susceptible and extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae
Tebipenem HBR
Impact of varied test conditions on the in vitro activity of tebipenem (SPR859) and meropenem against urinary pathogens, including those expressing extended-spectrum beta-lactamases (ESBL)
Tebipenem HBR
In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative bacteria
Tebipenem HBR
Characterization of the mechanism of action of tebipenem (SPR859) in the Escherichia coli macromolecular synthesis assay
Tebipenem HBR
In vivo characterization of tebipenem-pivoxil (SPR994) in a murine ascending Escherichia coli urinary tract model
Tebipenem HBR
In vitro bactericidal activity and post-antibiotic effect of tebipenem (SPR859) against susceptible and extended-spectrum beta-lactamase producing Enterobacteriaceae as compared to levofloxacin (LVX) and meropenem (MEM)
Tebipenem HBR
Antimicrobial activity assessment of tebipenem (SPR859) against an isolate collection causing urinary tract infections
SPR720
Treatment of Mycobacterium avium subspecies hominissuis (MAH) infection with a novel gyrase inhibitor (SPR719/SPR720) was associated with a significant decrease in bacterial load as assessed in macrophages, biofilm and in mice
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem for multi-drug resistant Enterobacteriaceae
Tebipenem HBR
Dose ranging and dose fractionation of tebipenem-pivoxil (SPR994) in neutropenic murine thigh models of gram-negative bacterial infection
SPR720
In vitro characterization of a novel gyrase inhibitor (SPR719) against nontuberculous Mycobacteria
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection
SPR720
Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection
Rex JH, Talbot GH, Goldberger MJ, et al. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017 Jul 1;65(1):141-146.
SPR206
Zabawa TP, Pucci MJ, Parr TR Jr, Lister T. Treatment of Gram-negative bacterial infections by potentiation of antibiotics. Curr Opin Microbiol. 2016 Oct;33:7-12.
Pucci MJ, Dougherty TJ. Editorial overview: Antimicrobials: fighting bacterial infections in the 21st century-thinking outside of the box. Curr Opin Microbiol. 2016 Oct;33:v-vii
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
